CDK4 and neoplasm: While the majority of studies examining the immunomodulatory activity of CDK4/6 inhibition focused on tumor-intrinsic effects or effects on the tumor microenvironment more broadly, a seminal article in 2018 reported on the direct impact of CDK4/6 inhibition on T cells (111).